Tacrolimus (FK506) inhibits interleukin-1β-induced angiopoietin-1, Tie-2 receptor, and vascular endothelial growth factor through down-regulation of JNK and p38 pathway in human rheumatoid fibroblast-like synoviocytes

Joint Bone Spine

Volumn 79, Issue 2, 2012, Pages 137-143

  Choe, Jung Yoon ^a   Lee, Seung Jin ^a   Park, Sung Hoon ^a   Kim, Seong Kyu ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Angiopoietin 1; Rheumatoid arthritis; Tacrolimus; Tie 2 receptor; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN RECEPTOR; INTERLEUKIN 1BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; TACROLIMUS; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; WESTERN BLOTTING;

ANGIOPOIETIN-1; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; FIBROBLASTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MAP KINASE KINASE 4; NEOVASCULARIZATION, PATHOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, TIE-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNOVIAL MEMBRANE; TACROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84857798435     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2011.03.018     Document Type: Article

References (38)

1. Polverini P.J. The pathophysiology of angiogenesis. Crit Rev Oral Biol Med 1995, 6:230-247.
2. Koch A.E. Review: angiogenesis: implications for rheumatoid arthritis. Arthritis Rheum 1998, 41:951-962.
3. Maruotti N., Cantatore F.P., Crivellato E., et al. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006, 21:557-566.
4. Hirohata S., Sakakibara J. Angioneogenesis as a possible elusive triggering factor in rheumatoid arthritis. Lancet 1999, 353:1331.
5. Fearon U., Griosios K., Fraser A., et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003, 30:260-268.
6. Scott B.B., Zaratin P.F., Colombo A., et al. Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2002, 29:230-239.
7. Gravallese E.M., Pettit A.R., Lee R., et al. Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor α. Ann Rheum Dis 2003, 62:100-107.
8. Scott B.B., Zaratin P.F., Gilmartin A.G., et al. TNF-α modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-κB signalling pathway. Biochem Biophys Res Commun 2005, 328:409-414.
9. DeBusk L.M., Chen Y., Nishishita T., et al. Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor alpha-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum 2003, 48:2461-2471.
10. Shahrara S., Volin M.V., Connors M.A., et al. Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res 2002, 4:201-208.
11. Chen Y., Donnelly E., Kobayashi H., et al. Gene therapy targeting the Tie2 function ameliorates collagen-induced arthritis and protects against bone destruction. Arthritis Rheum 2005, 52:1585-1594.
12. Bottomley M.J., Webb N.J., Watson C.J., et al. Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-α (TNF-α) in synovial fluid. Clin Exp Immunol 1999, 117:171-176.
13. Paleolog E.M., Young S., Stark A.C., et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998, 41:1258-1265.
14. Cho M.L., Cho C.S., Min S.Y., et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002, 46:1202-1209.
15. Fava R.A., Olsen N.J., Spencer-Green G., et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994, 180:341-346.
16. Ben-Av P., Crofford L.J., Wilder R.L., et al. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett 1995, 372:83-87.
17. Berse B., Hunt J.A., Diegel R.J., et al. Hypoxia augments cytokine (transforming growth factor-β (TGF-β) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin Exp Immunol 1999, 115:176-182.
18. Nagashima M., Wauke K., Hirano D., et al. Effects of combinations of anti-rheumatic drugs on the production of vascular endothelial growth factor and basic fibroblast growth factor in cultured synoviocytes and patients with rheumatoid arthritis. Rheumatology (Oxford) 2000, 39:1255-1262.
19. Macías I., García-Pérez S., Ruiz-Tudela M., et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor-α blockade in patients with rheumatoid arthritis. J Rheumatol 2005, 32:2102-2108.
20. Hirata S., Matsubara T., Saura R., et al. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989, 32:1065-1073.
21. Nakahara H., Song J., Sugimoto M., et al. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 2003, 48:1521-1529.
22. Scott L.J., McKeage K., Keam S.J., et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003, 63:1247-1297.
23. Kapp A., Allen B.R., Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat 2003, 14:5-16.
24. Tocci M.J., Matkovich D.A., Collier K.A., et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol 1989, 143:718-726.
25. Diestel A., Roessler J., Pohl-Schickinger A., et al. Specific p38 inhibition in stimulated endothelial cells: a possible new anti-inflammatory strategy after hypothermia and rewarming. Vascul Pharmacol 2009, 51:246-252.
26. Fukushima H., Hirano T., Oka K. Staphylococcus aureus-superantigen decreases FKBP51 mRNA expression and cell-response to suppressive efficacy of a glucocorticoid in human peripheral blood mononuclear cells: possible implication of mitogen-activated protein kinase pathways. Eur J Pharmacol 2007, 570:222-228.
27. Yang C.W., Ahn H.J., Jung J.Y., et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. Transplantation 2003, 75:20-24.
28. Suri C., Jones P.F., Patan S., et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996, 87:1171-1180.
29. Sato T.N., Tozawa Y., Deutsch U., et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature 1995, 376:70-74.
30. Coxon A., Bolon B., Estrada J., et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 2002, 46:2604-2612.
31. Morel J., Berenbaum F. Signal transduction pathways: new targets for treating rheumatoid arthritis. Joint Bone Spine 2004, 71:503-510.
32. Hernández G.L., Volpert O.V., Iñiguez M.A., et al. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001, 193:607-620.
33. Yamauchi J., Takai S., Matsushima-Nishiwaki R., et al. Tacrolimus but not cyclosporine A enhances FGF-2-induced VEGF release in osteoblasts. Int J Mol Med 2009, 23:267-272.
34. Rajnoch J., Lodererova A., Szabo A., et al. Regulators of angiogenesis in renal ischemia/reperfusion injury in normotensive and hypertensive rats: effect of tacrolimus. Transplant Proc 2005, 37:352-354.
35. Wang Y., Yang S., Wu L., et al. Topical tacrolimus suppresses the expression of vascular endothelial growth factor and insulin-like growth factor-1 in late anagen. Clin Exp Dermatol 2009, 34:e937-e940.
36. Turgut B., Guler M., Akpolat N., et al. The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization. Curr Eye Res 2011, 36:34-40.
37. Sawada S., Suzuki G., Kawase Y., et al. Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 1987, 139:1797-1803.
38. Schett G., Tohidast-Akrad M., Smolen J.S., et al. Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. Arthritis Rheum 2000, 43:2501-2512.